M Loftus, RS Brown Jr, NS El-Farra… - Gastroenterology & …, 2023 - ncbi.nlm.nih.gov
Cirrhosis, or advanced scarring of the liver, represents the end stage of chronic liver disease and is associated with high morbidity and mortality. Hepatorenal syndrome–acute kidney …
O Berger, W Choi, CH Ko, MP Thompson… - ACS Pharmacology & …, 2024 - ACS Publications
Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver disease first reported over a century ago, but its management still poses an unmet challenge. A …
A Sohal, H Chaudhry, D Dukovic, KV Kowdley - JGH Open, 2023 - Wiley Online Library
Abstract Background and Aim Hepatorenal syndrome (HRS) is a life‐threatening complication of advanced liver disease. This study aimed to examine the impact of hospital …
U Farooq, ZI Tarar, AJ Chaudhary, AE Alayli, F Kamal… - Livers, 2024 - mdpi.com
Hepatorenal syndrome (HRS) is a unique form of renal dysfunction that results from circulatory hemodynamic dysfunction in advanced liver disease. We aimed to determine …
KM Cooper, A Colletta, K Moulton… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Kidney disease in patients with liver disease is serious and increases mortality. Up to 50% of patients hospitalized experience an episode of acute kidney injury. In general, men with liver …
A Sabry, E Abdelsameea, S Rashad… - … Journal of Medical …, 2024 - ijma.journals.ekb.eg
Introduction: Hepatorenal syndrome [HRS] is a severe form of functional kidney failure that occurs in advanced liver cirrhosis and is associated with poor prognosis. Early recognition …
Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases …
–Three scientific abstracts via one oral and two poster presentations detail the Company's latest clinical research findings on the therapeutic effect of TERLIVAZ for adults with HRS …
T Idee, DAXK veränderte Lage - Development, 2023 - finanzen.ch
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice …